NCT03335774View on ClinicalTrials.gov

Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

March 5, 2021

Study Completion Date

March 5, 2021

Conditions
Internal Hemorrhoids
Interventions
DRUG

Hydrocortisone Acetate Suppository, 25 mg (Nivagen)

One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).

DRUG

Placebo (Vehicle) Suppository (Nivagen)

One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).

Trial Locations (2)

28217

Clinical Research, Charlotte

400701

Clinical Research, Navi Mumbai

Sponsors
All Listed Sponsors
lead

Nivagen Pharmaceuticals Inc.

INDUSTRY